REDEMPLO (plozasiran sodium)
Redemplo helps adults with familial chylomicronemia syndrome (FCS) manage high triglyceride levels alongside dietary changes. It is used to lower triglycerides in patients with this specific condition. This medication provides a targeted approach to reducing fats in the blood by focusing on the underlying protein production.
How REDEMPLO Works
Redemplo works by using RNA interference to break down the messenger RNA responsible for producing the apoC-III protein. By reducing the amount of this protein in the liver and blood, the drug allows the body to more effectively clear triglycerides from the bloodstream.
Details
- Status
- Prescription
- First Approved
- 2025-11-18
- Patent Cliff
- 2038
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
REDEMPLO Approval History
What REDEMPLO Treats
1 indicationsREDEMPLO is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Familial Chylomicronemia Syndrome
REDEMPLO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to REDEMPLO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REDEMPLO FDA Label Details
Indications & Usage
FDA Label (PDF)REDEMPLO is indicated for the treatment of Familial Chylomicronemia Syndrome.
REDEMPLO Patents & Exclusivity
Patents (5 active)
Pro Intelligence Preview
Deep insights for REDEMPLO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2038
- • 5 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 1 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.